MADRID — Amgen’s Imdelltra combined with AstraZeneca’s Imfinzi slashed the chances of dying by 58% versus Imfinzi alone in the first-line maintenance setting in certain small …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.